Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Operating Income (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Operating Income for 6 consecutive years, with -$60.6 million as the latest value for Q4 2025.

  • Quarterly Operating Income rose 28.65% to -$60.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$302.7 million through Dec 2025, up 18.72% year-over-year, with the annual reading at -$302.7 million for FY2025, 18.72% up from the prior year.
  • Operating Income for Q4 2025 was -$60.6 million at Relay Therapeutics, up from -$80.4 million in the prior quarter.
  • The five-year high for Operating Income was -$42.4 million in Q1 2021, with the low at -$193.6 million in Q2 2021.
  • Average Operating Income over 5 years is -$85.6 million, with a median of -$82.6 million recorded in 2025.
  • The sharpest move saw Operating Income tumbled 598.37% in 2021, then surged 59.8% in 2022.
  • Over 5 years, Operating Income stood at -$67.7 million in 2021, then dropped by 7.57% to -$72.9 million in 2022, then decreased by 26.55% to -$92.2 million in 2023, then increased by 7.83% to -$85.0 million in 2024, then increased by 28.65% to -$60.6 million in 2025.
  • According to Business Quant data, Operating Income over the past three periods came in at -$60.6 million, -$80.4 million, and -$76.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.